7 results about "Dosing interval" patented technology

The invention discloses a Rurugolil long-acting preparation composition as well as a preparation method and application thereof. The composition comprises an active medicine and at least one suspending aid. The Rurugolil long-acting preparation composition has an excellent slow-release effect, the administration interval can be prolonged to 7-90 days per time from 1 day per time, and the bioavailability, the compliance and the safety of a patient are remarkably improved. The pharmaceutical composition disclosed by the invention has the advantages of high preparation stability, simple prescription, controllable preparation process and capability of realizing industrial production amplification.

We provide a combination containing meloxicam and rizatriptan. [Solution] A composition is disclosed comprising an NSAID such as meloxicam and / or rizatriptan in combination with cyclodextrin and / or carbonate or bicarbonate. These compositions can be administered orally to improve the bioavailability or pharmacokinetics of NSAIDs for the treatment of pain such as migraines, arthritis, and other conditions. Also provided is a method for treating pain such as migraines, comprising administering meloxicam and rizatriptan to a person suffering from pain such as migraines. These methods may be particularly useful when administering meloxicam and rizatriptan while a person is suffering from an acute migraine attack or aura. In some embodiments, the combination of meloxicam and rizatriptan is used, with meloxicam being T max It may be administered so that the time interval is 3 hours or less.

Disclosed in the present invention are a long-acting formulation composition of Relugolix, a preparation method therefor, and use thereof. The composition comprises an active drug and at least one suspending agent. The long-acting formulation composition of Relugolix of the present invention has an excellent sustained-release effect, can prolong the administration interval from 1 day / time to 7 days to 90 days / time, and significantly improves the bioavailability, compliance, and safety of patients. The pharmaceutical composition of the present invention has the advantages of high formulation stability, simple prescription, controllable preparation process, and scale-up capability for industrial production.

This invention relates to a drug for treating ANCA-associated vasculitis (AAV) using an effective dose of the drug, administration regimen, administration interval, and dosage form targeting BlyS and / or APRIL. The provided effective dose of the drug targeting BlyS and / or APRIL has been demonstrated to exhibit good safety and therapeutic efficacy in the treatment or relief of patients with ANCA-associated vasculitis.

In the treatment of patients with tumors (especially malignant tumors), the substances phenoxythiamine (B-OT) and / or oxothiamine (OT) are administered as active ingredients concurrently with ongoing radionuclide therapy (RNT) (particularly radioimmunotherapy (RIT) and / or radiopeptide or radioligand or radiopeptide ligand therapy (RLT)). B-OT and / or OT administration is cyclical, meaning that dosing phases of B-OT and / or OT (“B-OT / OT dosing cycles”) alternate with treatment intervals (dosing intervals). During each B-OT / OT dosing cycle, B-OT and / or OT are administered at a predetermined dose (mg / kg patient body weight) for one or more consecutive days. This is followed by a treatment interval during which neither B-OT nor OT is administered, before the next B-OT / OT dosing cycle begins.

This invention relates to the field of medical information management technology, specifically to an intelligent verification method and system for vaccine administration processes. In this invention, isolated operation logs during the vaccination process are reconstructed into a complete sequence of recipient vaccination behaviors based on their inherent temporal correlation and the homology of the executing entities. A Hidden Markov Model is then used to perform in-depth analysis of this sequence, inferring the underlying vaccination stage states that conform to clinical logic from the observed specific behaviors. This elevates verification from static data checking to a dynamic process review. Furthermore, the inferred actual stage sequence is rigorously compared with the standardized process in three dimensions: stage completeness, sequential accuracy, and dose interval. Innovatively, a probability confidence level is calculated for any identified process deviations, achieving a quantitative assessment of abnormal behavior.

The present invention relates to a composition for treating joint diseases and a preparation method therefor and, more specifically, to a composition comprising a cross-linked hyaluronic acid hydrogel obtained by a cross-linking reaction between hyaluronic acid or a pharmaceutically acceptable salt thereof and an alkylene diamine cross-linking agent, and a preparation method therefor. The composition has a storage modulus (G', 2.5 Hz, 25° C) of 250-850 Pa, has a degree of cross-linking (CrD; number of cross-linking agents bound to both sides / number of hyaluronic acid units) of less than 5 mol %, and exhibits an effect of alleviating symptoms of joint diseases for a period of 3 months or longer when administered once as an injectable formulation to a patient. The composition has a low degree of crosslinking that allows flexible adjustment of the dosing interval while maintaining high biocompatibility, in vivo persistence, and a clinically meaningful storage modulus, thereby reducing patient burden caused by frequent administration and being expected to provide an excellent clinical effect of alleviating joint disease symptoms for three months or longer.